FDA tells a Louisiana court the mifepristone review will be finished by March 2027

The U.S. Food and Drug Administration expects to finish its safety review of mifepristone by March 2027. It said so in a filing in federal court in Louisiana late on Wednesday. The agency expects the results of a study on the drug's risks in December, and it will write a report after it has interpreted them.

Mifepristone has been approved in the United States since 2000. It is taken with misoprostol to end a pregnancy. A 2023 rule let clinicians prescribe it at a remote visit and let pharmacies send it by mail. The review described in Wednesday's filing could support a later decision to repeal that rule. The agency could also reopen the 2000 approval. Reuters noted that reversing an original approval would be a long and difficult process, separate from changing the conditions of use.

The study design is the part of the filing with a number. The FDA said it is comparing a sample of 100,000 women who used mifepristone with a comparator group who had surgical abortions. It said it is running a statistical analysis to look for safety risks that have not yet been identified. A sample of that size is large enough to detect uncommon events. It does not, by itself, decide what counts as a risk large enough to change a label.

December is the date for the study results. March 2027 is the date for the completed review. The gap is the interpretation. A report that lands in March, after a December data drop, is the document a court and a future commissioner would use. The filing does not promise a withdrawal, a new restriction, or a confirmation of the current label. It promises a finished review on that calendar.

The case is in Louisiana. The state's involvement is the reason a federal filing there now sets the public timetable. Abortion law after the end of Roe v. Wade is a state map. Mifepristone is the drug that crosses it, because a mailed packet does not stop at a state line unless the rules for prescribing and dispensing are tightened. That is why a mail rule from 2023 is the regulation most directly in the path of this review.

A remote prescription needs a clinician, a pharmacy and a carrier. Repealing the 2023 conditions would put the drug back under the older in-person requirements, if the agency chose that route. Leaving the 2000 approval in place while changing the conditions is the narrower action. Reopening the approval itself would ask whether the drug should be on the market at all. The filing keeps both possibilities open and dates only the review, not the decision.

The 100,000-woman sample is not the full set of users since 2000. It is the study group named in the filing. The comparator is surgical abortion, not childbirth and not an untreated pregnancy. That choice sets what the analysis can say. It can compare outcomes against a procedure. It cannot, on this design, answer a question about carrying a pregnancy to term. Readers of the December results will need that frame, because a risk measured against surgery is not a risk measured against birth.

No interim figure was released with the filing. The agency did not say how many of the 100,000 records are already in hand. It said it expects results in December. Between Wednesday and that month, the mail rule remains in force. The political fact is the date. A review that ends in March 2027 lands after the November 2026 midterm elections and inside the next congressional session.

The drug's two-decade record is the baseline the study is being asked to test. What changed on Wednesday is the calendar: December for the numbers, March 2027 for the report, and a Louisiana case as the place that calendar was written down.